Maxim lowered the firm’s price target on Oncolytics (ONCY) to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model to reflect the expected dilution from the company needing to raise capital in the near-term to fund its cancer programs, the analyst tells investors in a research note. Maxim adds however that it remains positive on the opportunities for Oncolytics in pela in breast and pancreatic cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics Biotech’s Financial Stability at Risk: Urgent Need for New Financing
- Oncolytics Biotech Advances Cancer Trials with Promising Results
- Oncolytics Biotech’s Earnings Call: Clinical Progress Amid Challenges
- Oncolytics reports Q4 EPS (10c) vs. (5c) last year
- Oncolytics Biotech (ONCY) Q4 Earnings Cheat Sheet